Table 2. Relationship between clinico-pathological parameters and clinical outcome measures.

	Univariate analysis
Clinico-pathological characteristic	Time to biochemical relapseP value, Hazard Ratio (95% CI)	Survival from biochemical relapseP value, Hazard Ratio (95% CI)	Disease-specific survivalP value, Hazard Ratio (95% CI)
Age (<70/>70)	0.260, 1.40, (0.8-2.5)	0.385, 1.44, (0.6-3.3)	0.020, 2.11, (1.1-4.0)
Gleason (<7/7/>7)	0.004, 1.94, (1.3-2.9)	0.060, 1.48, (0.8-2.6)	0.007, 1.91, (1.3-2.9)
PSA at diagnosis (<10/10/>10)	0.002, 1.96, (1.3-2.9)	0.078, 1.46, (0.8-2.7)	0.001, 2.04, (1.3-3.3)
Lymphovascular invasion (no/yes)	0.001, 4.6, (1.7-11.6)	0.612, 1.32, (0.5-3.9)	0.114, 2.09, (0.8-5.3)
PSA at recurrence (<10/10/>10)		<0.001, 5.86, (2.8-12.2)	<0.001, 2.82, (1.9-4.2)
Metastases at any time (no/yes)	0.001, 3.65, (1.7-8.0)	0.008, 4.86, (1.4-17.4)	<0.001, 5.0, (2.0-12.4)
Ki67 (≤median vs >median)	0.796, 1.08, (0.6-2.0)	0.185, 1.68, (0.8-3.6)	0.006, 2.28, (1.2-4.2)

The clinical variables were grouped and analysed by Kaplan Meier methods with reference to clinical outcome measures as shown. Patients were considered to have biochemical relapse dependent on treatment; radical prostatectomy serum PSA >0.2ng/ml, radical radiotherapy serum PSA of 2.0ng/ml above the post treatment nadir level, hormone treatment 2-3 consecutive rises in serum PSA levels above the nadir obtained at intervals of >2 weeks [28, 29]. Numbers in bold denote significant associations with p value <0.05.